---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044970"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T12:09:15.851986+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cingulate CFO & GC resign; pauses CTx-1301 trial; CEO salary cut 55%; warns of capital need

## Summary
- CFO Louis Van Horn retired Dec 13; General Counsel Craig Gilgallon resigned effective Dec 15.
- CEO Shane Schaffer base salary reduced 55% to $226,350; COO Laurie Myers reduced 50% to $212,000.
- Three directors (Gallagher, Givens, Medeiros) resigned.
- Clinical trial for CTx-1301 paused pending FDA guidance; expects ~$184k/month comp expense reduction.
- Company states no assurance of continued operations; needs significant capital; may file for bankruptcy.

## SEC filing metadata
- accession: 0001493152-23-044970
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315223044970/0001493152-23-044970-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315223044970/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044970
- JSON: https://secwatch.observer/filing/0001493152-23-044970.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044970.txt

## Key facts
- Executive change
  Craig S. Gilgallon resigned as General Counsel at Cingulate Inc..
  - Action: resigned
  - Role: General Counsel
  source text: On December 12, 2023, Craig S. Gilgallon, General Counsel, informed Cingulate Inc. (the “Company”) that he was resigning as an officer of the Company and was terminating employment with Cingulate Therapeutics LLC, a wholly-owned subsidiary of the Company, effective on December 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315223044970/0001493152-23-044970-index.htm
- Executive change
  Gregg Givens resigned as Director at Cingulate Inc..
  - Action: resigned
  - Role: Director
  source text: On December 13, 2023, each of Gregg Givens and Curt Medeiros provided the Company with notice of their resignation from the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315223044970/0001493152-23-044970-index.htm
- Executive change
  Curt Medeiros resigned as Director at Cingulate Inc..
  - Action: resigned
  - Role: Director
  source text: On December 13, 2023, each of Gregg Givens and Curt Medeiros provided the Company with notice of their resignation from the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315223044970/0001493152-23-044970-index.htm
- Executive change
  Patrick Gallagher resigned as Director at Cingulate Inc..
  - Action: resigned
  - Role: Director
  source text: On December 12, 2023, Patrick Gallagher provided the Company with notice of his resignation from the Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315223044970/0001493152-23-044970-index.htm
- Executive change
  Louis G. Van Horn retired as Chief Financial Officer at Cingulate Inc..
  - Action: retired
  - Role: Chief Financial Officer
  source text: On December 13, 2023, Louis G. Van Horn, Chief Financial Officer, retired from the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1862150/000149315223044970/0001493152-23-044970-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.